These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Aldosterone in vascular and metabolic dysfunction. Luther JM Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):16-21. PubMed ID: 26575396 [TBL] [Abstract][Full Text] [Related]
24. Aldosterone receptor antagonists: current perspectives and therapies. Guichard JL; Clark D; Calhoun DA; Ahmed MI Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977 [TBL] [Abstract][Full Text] [Related]
25. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. Piotrowski DW J Med Chem; 2012 Sep; 55(18):7957-66. PubMed ID: 22866979 [No Abstract] [Full Text] [Related]
26. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194 [TBL] [Abstract][Full Text] [Related]
28. Insufficient use of mineralocorticoid receptor antagonists ın patients that underwent renal sympathetic denervation for resistant hypertension. Bacaksiz A; Uyarel H Int J Cardiol; 2014 May; 173(2):336. PubMed ID: 24680253 [No Abstract] [Full Text] [Related]
29. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348 [TBL] [Abstract][Full Text] [Related]
30. Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria-A Path for Improved Renoprotection? Rossing P; Persson F Am J Med Sci; 2018 May; 355(5):407-408. PubMed ID: 29753367 [No Abstract] [Full Text] [Related]
33. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure. Young MJ; Kanki M; Karthigan N; Konstandopoulos P Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730 [TBL] [Abstract][Full Text] [Related]
34. Role of mineralocorticoid receptor antagonists in kidney diseases. Patel V; Joharapurkar A; Jain M Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798 [TBL] [Abstract][Full Text] [Related]
35. Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. Kawarazaki H; Ando K; Nagae A; Fujita M; Matsui H; Fujita T Nephrol Dial Transplant; 2010 Sep; 25(9):2879-89. PubMed ID: 20466668 [TBL] [Abstract][Full Text] [Related]
36. Mineralocorticoid receptor modulators: a patent review (2007 - 2012). Collin M; Niemann F; Jaisser F Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301 [TBL] [Abstract][Full Text] [Related]
37. Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. Valaiyapathi B; Calhoun DA Curr Hypertens Rep; 2018 Mar; 20(3):23. PubMed ID: 29556729 [TBL] [Abstract][Full Text] [Related]
38. New insights on the renal protective effects of mineralocorticoid receptor antagonists. Maiolino G; Calò LA J Hypertens; 2019 Jan; 37(1):9-10. PubMed ID: 30499917 [No Abstract] [Full Text] [Related]